Company Overview of Icon Bioscience, Inc.
Icon Bioscience, Inc. operates as a specialty biopharmaceutical company focusing on the development and commercialization of ophthalmic pharmaceuticals in the United States. The company’s products include IBI-10090, a biodegradable therapeutic for injection of dexamethasone into the anterior chamber to treat inflammation associated with cataract surgery; IBI-20089, an injectable intraocular sustained release product for the delivery of triamcinolone acetonide; IBI-60089, a biodegradable product for the delivery of therapeutic levels of latanoprost to the anterior chamber; and IBI-80090 (mephalan for intraocular injection) for the treatment of retinoblastoma. It also develops products to trea...
1253 Reamwood Avenue
Sunnyvale, CA 94089
Founded in 2004
Key Executives for Icon Bioscience, Inc.
Chief Executive Officer and President
Vice President of Finance & Administration
Vice President of Clinical Development
Manufacturing & Operations Advisor
Compensation as of Fiscal Year 2014.
Icon Bioscience, Inc. Key Developments
Icon Bioscience, Inc. Completes Treatment in its Pivotal Phase 3 Study of IBI-10090
Oct 6 14
Icon Bioscience, Inc. announced that the last patient has completed treatment in its pivotal Phase 3 study of IBI-10090. Top-line data is expected to be reported in the fourth quarter of 2014. Employing Icon's Verisome technology, IBI-10090 is designed to provide a controlled, sustained-release formulation of the anti-inflammatory agent dexamethasone into the anterior chamber of the eye through a single injection administered immediately following cataract surgery.
Icon Bioscience Announces Early Completion of Patient Enrollment in its Phase 3 Study of IBI-10090
Jun 30 14
Icon Bioscience, Inc. announced the completion of patient enrollment in its pivotal phase 3 study of IBI-10090, approximately four months ahead of projected timelines. IBI-10090, which employs the Verisome technology, is Icon's lead pipeline product. It has been designed to provide a controlled, sustained-release formulation of the anti-inflammatory agent dexamethasone into the anterior chamber of the eye through a single injection administered immediately following cataract surgery. With some three million cataract surgeries performed annually in the US alone, IBI-10090 addresses a potentially large market. Moreover, the current standard of care for inflammation associated with cataract surgery involves a comparatively burdensome process of patient administered eye drops applied topically several times daily over an extended time period.
David S. Tierney Joins Icon Bioscience, Inc. as President & Chief Executive Officer
Apr 7 14
Icon Bioscience, Inc. announced that David S. Tierney, MD joined the company as President & Chief Executive Officer. Previously, Dr. Tierney served as President & COO of Oceana Therapeutics, Inc., a company he co-founded in mid-2008.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries